Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia (Q42905606)

10 November 2017

title

Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia (English)

1 reference

10 November 2017

1 reference

1 reference

3

Min Ja Kim

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20846586

14 July 2024

author name string

Vasyl Melnyk

2

1 reference

10 November 2017

Oleksiy Datsenko

4

1 reference

10 November 2017

Oleksandr Dzyublik

5

1 reference

10 November 2017

Felix Glumcher

6

1 reference

10 November 2017

Yin-Ching Chuang

7

1 reference

10 November 2017

Gary Dukart

9

1 reference

10 November 2017

Nathalie Dartois

12

1 reference

10 November 2017

Hassan Gandjini

13

1 reference

10 November 2017

311 Study Group

14

1 reference

10 November 2017

Antonio T. Freire

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20846586

14 July 2024

Robert T. Maroko

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20846586

14 July 2024

C. Angel Cooper

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20846586

14 July 2024

Joan M. Korth-Bradley

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20846586

14 July 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20846586

14 July 2024

publication date

1 October 2010

1 reference

full work available at URL

10 November 2017

https://api.elsevier.com/content/article/PII:S0732889310002099?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/J.DIAGMICROBIO.2010.05.012

https://api.elsevier.com/content/article/PII:S0732889310002099?httpAccept=text/plain

14 July 2024

1 reference

https://api.crossref.org/works/10.1016/J.DIAGMICROBIO.2010.05.012

Diagnostic Microbiology and Infectious Disease

14 July 2024

published in

1 reference

10 November 2017

volume

68

1 reference

10 November 2017

issue

2

1 reference

10 November 2017

page(s)

140-151

1 reference

Guidelines for the Management of Adults with Hospital-acquired, Ventilator-associated, and Healthcare-associated Pneumonia

10 November 2017

cites work

1

1 reference

https://api.crossref.org/works/10.1016/J.DIAGMICROBIO.2010.05.012

The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data

14 July 2024

2

1 reference

https://api.crossref.org/works/10.1016/J.DIAGMICROBIO.2010.05.012

Tigecycline possibly underdosed for the treatment of pneumonia: a pharmacokinetic viewpoint

14 July 2024

3

1 reference

https://api.crossref.org/works/10.1016/J.DIAGMICROBIO.2010.05.012

Nosocomial pneumonia. A multivariate analysis of risk and prognosis.

14 July 2024

4

1 reference

https://api.crossref.org/works/10.1016/J.DIAGMICROBIO.2010.05.012

Mortality and time to extubation in severe hospital-acquired pneumonia.

14 July 2024

5

1 reference

https://api.crossref.org/works/10.1016/J.DIAGMICROBIO.2010.05.012

Steady-state serum and intrapulmonary pharmacokinetics and pharmacodynamics of tigecycline

14 July 2024

6

1 reference

https://api.crossref.org/works/10.1016/J.DIAGMICROBIO.2010.05.012

Preventing nosocomial pneumonia: state of the art and perspectives for the 1990s

14 July 2024

7

1 reference

https://api.crossref.org/works/10.1016/J.DIAGMICROBIO.2010.05.012

Late onset ventilator-associated pneumonia due to multidrug-resistant Acinetobacter spp.: experience with tigecycline

14 July 2024

8

1 reference

https://api.crossref.org/works/10.1016/J.DIAGMICROBIO.2010.05.012

Activities of tigecycline (GAR-936) against Legionella pneumophila in vitro and in guinea pigs with L. pneumophila pneumonia

14 July 2024

9

1 reference

https://api.crossref.org/works/10.1016/J.DIAGMICROBIO.2010.05.012

The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam

14 July 2024

10

1 reference

https://api.crossref.org/works/10.1016/J.DIAGMICROBIO.2010.05.012

Tigecycline in combination with other antimicrobials: a review of in vitro, animal and case report studies

14 July 2024

11

1 reference

https://api.crossref.org/works/10.1016/J.DIAGMICROBIO.2010.05.012

Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin. The Severe Pneumonia Study Group.

14 July 2024

12

1 reference

https://api.crossref.org/works/10.1016/J.DIAGMICROBIO.2010.05.012

Antimicrobial activity of tigecycline (GAR-936) tested against 3498 recent isolates of Staphylococcus aureus recovered from nosocomial and community-acquired infections

14 July 2024

13

1 reference

https://api.crossref.org/works/10.1016/J.DIAGMICROBIO.2010.05.012

Pefloxacin versus imipenem in the therapy of nosocomial lung infections of intensive care unit patients

14 July 2024

14

1 reference

https://api.crossref.org/works/10.1016/J.DIAGMICROBIO.2010.05.012

Comparative clinical trial of ceftazidime and imipenem/cilastatin in patients with severe nosocomial pneumonias and septicaemias

14 July 2024

15

1 reference

https://api.crossref.org/works/10.1016/J.DIAGMICROBIO.2010.05.012

The attributable morbidity and mortality of ventilator-associated pneumonia in the critically ill patient. The Canadian Critical Trials Group

14 July 2024

16

1 reference

https://api.crossref.org/works/10.1016/J.DIAGMICROBIO.2010.05.012

Comparison of piperacillin/tazobactam and imipenem/cilastatin, both in combination with tobramycin, administered every 6 h for treatment of nosocomial pneumonia

14 July 2024

17

1 reference

https://api.crossref.org/works/10.1016/J.DIAGMICROBIO.2010.05.012

The SUPPORT prognostic model. Objective estimates of survival for seriously ill hospitalized adults. Study to understand prognoses and preferences for outcomes and risks of treatments

14 July 2024

18

1 reference

https://api.crossref.org/works/10.1016/J.DIAGMICROBIO.2010.05.012

Pharmacodynamic profile of tigecycline against methicillin-resistant Staphylococcus aureus in an experimental pneumonia model

14 July 2024

19

1 reference

https://api.crossref.org/works/10.1016/J.DIAGMICROBIO.2010.05.012

Pharmacodynamic evaluation of tigecycline against Acinetobacter baumannii in a murine pneumonia model

14 July 2024

20

1 reference

https://api.crossref.org/works/10.1016/J.DIAGMICROBIO.2010.05.012

A pharmacodynamic simulation to assess tigecycline efficacy for hospital-acquired pneumonia compared with other common intravenous antibiotics

14 July 2024

21

1 reference

https://api.crossref.org/works/10.1016/J.DIAGMICROBIO.2010.05.012

Pharmacologic treatment options for nosocomial pneumonia involving methicillin-resistant Staphylococcus aureus.

14 July 2024

22

1 reference

https://api.crossref.org/works/10.1016/J.DIAGMICROBIO.2010.05.012

Exposure-response analyses of tigecycline efficacy in patients with complicated skin and skin-structure infections

14 July 2024

23

1 reference

https://api.crossref.org/works/10.1016/J.DIAGMICROBIO.2010.05.012

Pharmacokinetics of Tigecycline after Single and Multiple Doses in Healthy Subjects

14 July 2024

25

1 reference

https://api.crossref.org/works/10.1016/J.DIAGMICROBIO.2010.05.012

Exposure-response analyses of tigecycline efficacy in patients with complicated intra-abdominal infections

14 July 2024

26

1 reference

https://api.crossref.org/works/10.1016/J.DIAGMICROBIO.2010.05.012

Results of a multicenter, randomized, open-label efficacy and safety study of two doses of tigecycline for complicated skin and skin-structure infections in hospitalized patients

14 July 2024

27

1 reference

https://api.crossref.org/works/10.1016/J.DIAGMICROBIO.2010.05.012

Investigational treatments for postoperative surgical site infections

14 July 2024

28

1 reference

https://api.crossref.org/works/10.1016/J.DIAGMICROBIO.2010.05.012

International Conference for the Development of Consensus on the Diagnosis and Treatment of Ventilator-associated Pneumonia

14 July 2024

29

1 reference

https://api.crossref.org/works/10.1016/J.DIAGMICROBIO.2010.05.012

Serum, tissue and body fluid concentrations of tigecycline after a single 100 mg dose

14 July 2024

30

1 reference

https://api.crossref.org/works/10.1016/J.DIAGMICROBIO.2010.05.012

Antimicrobial activity of tigecycline tested against nosocomial bacterial pathogens from patients hospitalized in the intensive care unit

14 July 2024

31

1 reference

https://api.crossref.org/works/10.1016/J.DIAGMICROBIO.2010.05.012

Integrated results of 2 phase 3 studies comparing tigecycline and levofloxacin in community-acquired pneumonia

14 July 2024

32

1 reference

https://api.crossref.org/works/10.1016/J.DIAGMICROBIO.2010.05.012

Population pharmacokinetics of tigecycline in patients with complicated intra-abdominal or skin and skin structure infections

14 July 2024

33

1 reference

https://api.crossref.org/works/10.1016/J.DIAGMICROBIO.2010.05.012

Community-associated methicillin-resistant Staphylococcus aureus

14 July 2024

34

1 reference

https://api.crossref.org/works/10.1016/J.DIAGMICROBIO.2010.05.012

Levofloxacin compared with imipenem/cilastatin followed by ciprofloxacin in adult patients with nosocomial pneumonia: A multicenter, prospective, randomized, open-label study

14 July 2024

35

1 reference

https://api.crossref.org/works/10.1016/J.DIAGMICROBIO.2010.05.012

14 July 2024

Identifiers

1 reference

10 November 2017

1 reference